Renesans peptydów a nowe cele terapeutyczne

• Autorzy: Krzywik J. , Katarzyńska J.
• Języki publikacji: PL

Słowa kluczowe

PL

peptydy; terapie peptydowe; oddziaływania białko białko

EN

peptides; peptide therapies; protein-protein interaction

• Wydawca: Politechnika Łódzka, Wydział Chemiczny
• Czasopismo: Eliksir
• Rocznik: 2015
• Tom: nr 2
• Strony: 15--22
• Opis fizyczny: Bibliogr. 37 poz., rys. kolor., wykr.

Twórcy

autor

Krzywik J.

• Instytut Chemii Organicznej, Wydział Chemiczny, Politechnika Łódzka

autor

Katarzyńska J.

• Instytut Chemii Organicznej, Wydział Chemiczny, Politechnika Łódzka

Bibliografia

• [1] Sewald N., Jakubke H.-D., Peptides: Chemistry and Biology, 2nd Edition, Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim 2009.
• [2] Dunn B.M., Peptide Chemistry and Drug design, 1st Edition, John Wiley&Sons Inc. 2015.
• [3] Craik D.J., Fairlie D.P., Liras S., Price D., 2013, The Future of Peptide-based Drugs, Chem. Biol. Drug Des., 81, 136 - 147.
• [4] Vlieghe P., Lisowski V., Martinez J., Khrestchatisky M., 2010, Synthetic therapeutic peptides: science and market, Drug Discov. Today, 15, 40 - 56.
• [5] Witt K.A., Gillespie T.J., Huber J.D., Egleton R.D., 2001, Davis T.P., Peptide drug modifications to enhance bioavailability and blood- -brain barrier permeability, Peptides, 22, 2329 - 2343.
• [6] Antosova Z., Mackova M., Kral V., Macek T., 2009, Therapeutic application of peptides and proteins: parenteral forever?, Trends Biotechnol., 27, 628 - 635.
• [7] Yin N., Brimble M.A., Harris P.WR., Wen J., 2014, Enhancing the Oral Bioavailability of Peptide Drugs by using Chemical Modification and Other Approaches, Med. Chem., 4, 763 - 769.
• [8] Uhlig T., Kyprianou T., Martinelli F.G., Oppici C.A., Heiligers D., Hills D., Calvo X.R., Verhaert P., 2014, The emergence of peptides in the pharmaceutical business: From exploration to exploitation, EuPA Open Proteom., 4, 58 - 69.
• [9] Sanvicens N., Marco M.P., 2008, Multifunctional nanoparticles - properties and prospects for their use in human medicine., Trends Biotechnol., 26, 425 - 433.
• [10] Lawson, C. and Wolf, S., 2009, ICAM-1 signaling in endothelial cells, Pharmacology Reports, 61, 22-32.
• [11] Liu, J.O., 2009, Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation, Immunological Reviews, 228, 184-198.
• [12] Bernstein, B.W., Bamburg, J.R., 2010, ADF/cofilin: a functional node in cell biology, Trends in Cell Biology, 20, 187 - 195.
• [13] Betz , U.A. , Farquhar , R., Ziegelbauer K., 2005, Genomics: success or failure to deliver drug targets?, Curr. Opin. Chem. Biol., 94, 387 - 391.
• [14] Pal A. , Chakrabarti P., Bahadur R., Rodier F. Janin J., 2007, Peptide segments in protein - protein interfaces, J. Biosci., 32, 101 - 111.
• [15] Smith M.C., Gestwicki J.E., 2012, Features of Protein-Protein Interactions that Translate into Potent Inhibitors: Topology, Surface Area and Affinity, Expert Rev. Mol. Med., 14, e16.
• [16] Jones , D.S. , Silverman , A.P., Cohran J.R., 2008, Developing therapeutic proteins by engineering ligand - recptor interactions, Trends Biotechnol., 26, 498 - 505.
• [17] Sillerud , L.O. and Larson , R.S., 2005, Design and structure of peptide and peptidomimetic antagonists of protein - protein interaction . Curr. Protein Pept. Sci. , 6, 151 - 169.
• [18] Baines , I.C. and Colas , P., 2006, Peptide aptamers as guides for small - molecule drug discovery . Drug Discov. Today, 11, 334 - 341.
• [19] Hummel G., Reineke U., Reimer U., Translating Peptides into Small Molecules in Exploiting Chemical Diversity for Drug Discovery, Royal Society of Chemistry, Cambrige 2006, 184-200.
• [20] Seet , B.T. , Dikic I., Zhou M.M., Pawson T., 2006, Reading protein modifications with interaction domains, Nat. Rev. Mol. Cell. Biol., 7, 473 - 483.
• [21] Chene P., 2006, Drugs targeting protein - protein interactions, ChemMedChem , 1, 400 - 411.
• [22] Bhat A., Roberts L.R., Dwyer J.J., 2015, Lead discovery and optimization strategies for peptide macrocycles, Europ. J. Med. Chem., 94, 471 - 479.
• [23] Lipovsek D., Pluckthun A., 2004, In-vitro protein evolution by ribosome display and mRNA display, J. Immunol. Methods, 290, 51 - 67.
• [24] Pasqualini R, Ruoslahti E., 1996, Organ targeting in vivo using phage display peptide libraries, Nature, 380, 364 - 366.
• [25] Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E., 2012, Targeting the prostate for destruction through a vascular address, Proc Natl Acad Sci U S A; 99, 1527 - 1531.
• [26] Terret N., 2013, Producing orally bioavailable biologics, Drug Discov. Dev., http://www.dddmag.com/articles/2013/05/producing- -orally-bioavailable-biologics, 30.10.2015.
• [27] PassiouraT.,Suga H., 2013, Flexizymes mediated genetic reprogramming as a tool for noncanonical peptide synthesis and drug discovery, Chem. Eur. J., 19, 6530 - 6536.
• [28] Funamoto S, Sasaki T, Ishihara S, Nobuhara M, Nakano M, Watanabe-Takahashi M, Saito T, Kakuda N, Miyasaka T, Nishikawa K, Saido TC, Ihara Y., 2013, Substrate ectodomain is critical for substrate preference and inhibition of g-secretase, Nat. Commun., 4, 3529 - 3541.
• [29] Josephson K., Ma Z. Wang Z., Sun Y., Tobe S., Perlmutter S., Vyasamneni R., Ye P., Boyer N., Arata M., Pattavina K., Seyb K., Zheng H., Sollomoni I., Nims E., de Koning E., Ricardo A., Treco D., 2013, Discovery of high affinity cyclic peptidomimetics binding Mcl-1 and Ras, Mol. Cancer Ther., 12, C212.
• [30] Scott C.P., Abel-Santos E., Wall M., Wahnon D.C., Benkovic S.J., 1999, Production of cyclic peptides and proteins in vivo, Proc. Natl. Acad. Sci., 96, 13638 - 13643.
• [31] Kritzer J.A., Hamamichi S., McCaffery J.M., Santagata S., Naumann T.A., Caldwell K.A., Caldwell G.A., Lindquist S., 2009, Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal model, Nat. Chem. Biol. 5, 655 - 663.
• [32] Lipiński, C.A., Lombardo F., Dominy B.W., Feeney P.J., 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 23, 3 - 25.
• [33] Veber, D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D., 2002, Molecular Properties that Influence the Oral Bioavailability of Drug Candidates, J. Med. Chem. 45, 2615 - 2623.
• [34] Lax R., 2013, The Future of Peptide Development in the Pharmaceutical Industry, PharManufacturing: Int. Peptide Rev., 10 - 15.
• [35] Kaspar A.A., Reichert J.M., 2013, Future directions for peptide therapeutics development, Drug Discov. Today 18, 807 - 817.
• [36] Tsomaia N., 2015, Peptide therapeutics: Targeting the undruggable space, Eur. J. Med. Chem., 94, 459 - 470.
• [37] Zhou Ch., Lu R., Lin G., Yao Z., 2011, The latest developments in synthetic peptides with immunoregulatory activities, Peptides 32, 408 - 414.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).